Novo Nordisk A/S (NVO) Trading With Heavy Volume Before Market Open

Trade-Ideas LLC identified Novo Nordisk A/S (NVO) as a pre-market mover with heavy volume candidate
By TheStreet Wire ,

Trade-Ideas LLC identified

Novo Nordisk A/S

(

NVO

) as a pre-market mover with heavy volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Novo Nordisk A/S as such a stock due to the following factors:

  • NVO has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $53.3 million.
  • NVO traded 124,679 shares today in the pre-market hours as of 8:48 AM, representing 13.2% of its average daily volume.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in NVO with the Ticky from Trade-Ideas. See the FREE profile for NVO NOW at Trade-Ideas

More details on NVO:

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity Care, and Biopharmaceuticals. The stock currently has a dividend yield of 1.3%. Currently there is 1 analyst that rates Novo Nordisk A/S a buy, no analysts rate it a sell, and 2 rate it a hold.

The average volume for Novo Nordisk A/S has been 1.4 million shares per day over the past 30 days. Novo Nordisk A/S has a market cap of $143.1 billion and is part of the health care sector and drugs industry. Shares are down 4.2% year-to-date as of the close of trading on Friday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Novo Nordisk A/S as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself.

Highlights from the ratings report include:

  • NVO's revenue growth has slightly outpaced the industry average of 14.4%. Since the same quarter one year prior, revenues rose by 14.8%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • NOVO NORDISK A/S has improved earnings per share by 5.5% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, NOVO NORDISK A/S increased its bottom line by earning $1.96 versus $1.64 in the prior year. This year, the market expects an improvement in earnings ($2.26 versus $1.96).
  • The net income growth from the same quarter one year ago has significantly exceeded that of the Pharmaceuticals industry average, but is less than that of the S&P 500. The net income increased by 1.8% when compared to the same quarter one year prior, going from $1,419.95 million to $1,445.17 million.
  • Net operating cash flow has significantly increased by 93.53% to $1,142.53 million when compared to the same quarter last year. In addition, NOVO NORDISK A/S has also vastly surpassed the industry average cash flow growth rate of -54.52%.
  • The gross profit margin for NOVO NORDISK A/S is currently very high, coming in at 84.44%. Regardless of NVO's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, NVO's net profit margin of 34.74% significantly outperformed against the industry.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Loading ...